Comparison of Continuation of Low-Molecular-Weight Heparin versus Switching to Unfractionated Heparin in the Peripartum

Abstract

Objective This study aimed to determine whether switching from low-molecular-weight heparin (LMWH) to unfractionated heparin (UFH) or its continuation in the peripartum affected anesthesia choice or bleeding complications.

Study Design A retrospective cohort study of 189 anticoagulated pregnant women who delivered at the University of Illinois at Chicago Hospital and Health Science System from 2005 to 2016. Demography, anesthesia choice, and bleeding complications were compared between the two groups.

Results There were 138 (73%) women on LMWH versus 51 (27%) who switched from LMWH to UFH during the peripartum. The demographics were similar, 123 women were on prophylactic: 81 (66%) were on LMWH and 42 (34%) switched to UFH. Of the 66 women on therapeutic anticoagulation, 57 (86%) continued on LMWH, while 9 (14%) switched to UFH. No difference in neuraxial anesthesia type received: 42 (82.4%) versus 108 (79.7%) women (odds ratio: 1.20, 95% confidence interval [CI]: 0.52–2.73, p = 0.837). Bleeding complications more than 1,000 mL, 6 versus 10% (relative risk [RR]: 0.58, 95% CI: 0.17–1.94, p = 0.380) and relaparotomy due to hemoperitoneum, 2% in either group (RR: 0.9, 95% CI: 0.10–8.48, p = 0.930) were similar in the two groups regardless of time of last injection.

Conclusion Anesthesia type and rate of bleeding complications were similar between women on LMWH and UFH during the peripartum.

Keywords

anticoagulation - pregnancy - low-molecular-weight heparin - unfractionated heparin - peripartum - bleeding complication - neuraxial anesthesia

• References

• 1 Creanga AA, Syverson C, Seed K, Callaghan WM. Pregnancy-related mortality in the United States, 2011-2013. Obstet Gynecol 2017; 130 (02) 366-373
• 2 American College of Obstetricians and Gynecologist. Inherited Thrombophilias in Pregnancy. Practice Bulletin Number 138, September, 2013
• 3 Kearon C, Akl EA, Comerota AJ. , et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e419S-e496S
• 4 Ayad SW, Hassanein MM, Mohamed EA, Gohar AM. Maternal and fetal outcomes in pregnant women with a prosthetic mechanical heart valve. Clin Med Insights Cardiol 2016; 10: 11-17
• 5 Nassar AH, Hobeika EM, Abd Essamad HM, Taher A, Khalil AM, Usta IM. Pregnancy outcome in women with prosthetic heart valves. Am J Obstet Gynecol 2004; 191 (03) 1009-1013
• 6 Vitale N, De Feo M, De Santo LS, Pollice A, Tedesco N, Cotrufo M. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol 1999; 33 (06) 1637-1641
• 7 Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106 (02) 401-407
• 8 Ginsberg JS, Kowalchuk G, Hirsh J, Brill-Edwards P, Burrows R. Heparin therapy during pregnancy. Risks to the fetus and mother. Arch Intern Med 1989; 149 (10) 2233-2236
• 9 Ginsberg JS, Hirsh J, Turner DC, Levine MN, Burrows R. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 1989; 61 (02) 197-203
• 10 Bates SM. Treatment and prophylaxis of venous thromboembolism during pregnancy. Thromb Res 2002; 108 (2-3): 97-106
• 11 Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e691S-e736S
• 12 Kominiarek MA, Angelopoulos SM, Shapiro NL, Studee L, Nutescu EA, Hibbard JU. Low-molecular-weight heparin in pregnancy: peripartum bleeding complications. J Perinatol 2007; 27 (06) 329-334
• 13 American College of Obstetricians and Gynecologist. Venous thromboembolism in pregnancy. ACOG Practice Bulletin Number 123 (2011, reaffirmed 2017
• 14 Kreppel D, Antoniadis G, Seeling W. Spinal hematoma: a literature survey with meta-analysis of 613 patients. Neurosurg Rev 2003; 26 (01) 1-49
• 15 Horlocker TT, Wedel DJ, Rowlingson JC, Enneking FK. Executive summary: regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 2010; 35 (01) 102-105
• 16 Horlocker TT, Wedel DJ. Neuraxial block and low-molecular-weight heparin: balancing perioperative analgesia and thromboprophylaxis. Reg Anesth Pain Med 1998; 23 (06) (Suppl. 02) 164-177
• 17 Horlocker TT, Wedel DJ, Benzon H. , et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 2003; 28 (03) 172-197
• 18 Butwick A, Hass C, Wong J, Lyell D, El-Sayed Y. Anticoagulant prescribing practices and anesthetic interventions among anticoagulated pregnant patients: a retrospective study. Int J Obstet Anesth 2014; 23 (03) 238-245
• 19 Roueli A, Cesario E, Amsellem J, Agman A, Vauthier-Brouzes D, Nizard J. Is a therapeutic anticoagulation window needed for delivery when using prophylactic low molecular weight heparin during pregnancy? A retrospective monocentric study. Eur J Obstet Gynecol Reprod Biol 2017; 215: 118-123
• 20 D'Angelo R, Smiley RM, Riley ET, Segal S. Serious complications related to obstetric anesthesia: the serious complication repository project of the Society for Obstetric Anesthesia and Perinatology. Anesthesiology 2014; 120 (06) 1505-1512
• 21 Cushman M, Lim W, Zakai NA. Clinical Practice Guideline on Anticoagulant Dosing and Management of Anticoagulant-Associated Bleeding Complications in Adults. Washington DC: American Society of Hematology; 2011
• 22 Duhl AJ, Paidas MJ, Ural SH. , et al; Pregnancy and Thrombosis Working Group. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 2007; 197 (05) 457.e1-457.e21
• 23 Brill-Edwards P, Ginsberg JS, Gent M. , et al; Recurrence of Clot in This Pregnancy Study Group. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N Engl J Med 2000; 343 (20) 1439-1444
• 24 Pacheco LD, Saade GR, Costantine MM, Vadhera R, Hankins GD. Reconsidering the switch from low-molecular-weight heparin to unfractionated heparin during pregnancy. Am J Perinatol 2014; 31 (08) 655-658
• 25 Bates SM, Geer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e691S-e736S
• 26 Leffert LR, Dubois HM, Butwick AJ, Carvalho B, Houle TT, Landau R. Neuraxial anesthesia in obstetric patients receiving thromboprophylaxis with unfractionated or low-molecular-weight heparin: a systematic review of spinal epidural hematoma. Anesth Analg 2017; 125 (01) 223-231
• 27 Rizk E, Wilson AD, Murillo MU, Putney DR. Comparison of antifactor Xa and activated partial thromboplastin time monitoring for heparin dosing in vascular surgery patients: a single-center retrospective study. Ther Drug Monit 2018; 40 (01) 151-155
• 28 Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy 2012; 32 (06) 546-558
• 29 Smythe MA, Priziola J, Dobesh PP, Wirth D, Cuker A, Wittkowsky AK. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis 2016; 41 (01) 165-186
• 30 Raschke RA, Guidry JR, Foley MR. Apparent heparin resistance from elevated factor VIII during pregnancy. Obstet Gynecol 2000; 96 (5 Pt 2): 804-806
• 31 Chunilal SD, Young E, Johnston MA. , et al. The APTT response of pregnant plasma to unfractionated heparin. Thromb Haemost 2002; 87 (01) 92-97
• 32 Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133 (6, Suppl): 454S-545S
• 33 Barbour LA, Kick SD, Steiner JF. , et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994; 170 (03) 862-869
• 34 Raagab AE, Mesbah YH, Brakat RI, Zayed AA, Alsaammani MA. Re-laparotomy after cesarean section: risk, indications and management options. Med Arh 2014; 68 (01) 41-43
• 35 Shinar S, Hareuveni M, Ben-Tal O, Many A. Relaparotomies after cesarean sections: risk factors, indications, and management. J Perinat Med 2013; 41 (05) 567-572